Michael John Appointed VP of Cardiovascular Regulatory Affairs of MCRA

Michael C. John, MPH, has been appointed new Vice President of Cardiovascular Regulatory Affairs.

Michael C. John, MPH joined MCRA from the US Food and Drug Administration, where he was Chief of the Interventional Cardiology Devices Branch. In his position, Michael supervised and provided leadership for a multi-disciplinary team of scientists and health care professionals on the regulation of interventional cardiovascular Class II and Class III medical devices. As Branch Chief, Michael reviewed and edited scientific memoranda from staff relating to all regulatory decisions on PMA, IDE, and 510(k) medical device submissions pertaining to coronary interventional products. He also functioned as a focal point for industry representatives, Advisory Panel members, scientific experts and cardiovascular thought leaders in discussing the regulation of products in the rapidly evolving interventional cardiovascular device arena.

Michael has extensive knowledge of medical device regulations and regulatory pathways to drive a device from conception to market. Prior to becoming Branch Chief, Michael was an Animal Testing Reviewer and Lead Reviewer in the Division of Cardiovascular Devices at FDA. Before joining FDA, Michael conducted cardiovascular research at The Massachusetts General Hospital in Boston, MA where he specialized in cardiovascular pathology and histology, and performed countless stent implantation procedures in animal models.

David Lown, MCRA’s General Manager said, “Beginning in 2004 MCRA has led the medical device model of deep industry specialization and service integration to assist industry in bringing innovation to patients. Michael is a recognized expert with an extensive background in cardiovascular device regulation and physiology, and his appointment reflects MCRA’s strong commitment to providing first-rate regulatory services to the cardiovascular community. We are honored Michael has joined MCRA. He will make a tremendous impact.”

Michael John said, “It is a privilege to join the distinguished team at MCRA at such an exciting time in the history of cardiovascular innovation,” said Michael John.  “MCRA has a long track record of success in the device arena and has established a strong foundation for growth into the cardiovascular field.  I look forward to leading the MCRA Cardio team to bring the next wave of innovative cardiovascular products and solutions to patients in need.”

WE WELCOME YOUR VIEWS

Please enter your comment!
Please enter your name here